P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study

I Vergote,J Korach,D O’Malley,Po Witteveen,A González Martin,R Coleman,D Cibula,R Madry,L Copeland,V Salutari,B Monk,J Sehouli,Ep Samartzis

doi:10.1136/ijgc-2019-esgo.215

P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study

I Vergote, J Korach + Show 11 more

https://doi.org/10.1136/ijgc-2019-esgo.215

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Nov 1, 2019
Citations: 1

Affiliation: Universitair Ziekenhuis Leuven, Sheba Medical Center, University Medical Center Utrecht, The University of Texas MD Anderson Cancer Center, Charles University, Agostino Gemelli University Polyclinic, University of Arizona, Charité - Universitätsmedizin Berlin, University Hospital of Zurich

#Clovis Oncology #In-field Region + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Introduction/BackgroundTumor Treating Fields (TTFields) are a non-invasive, regional antimitotic therapy. The Phase 2 INNOVATE study [NCT02244502] demonstrated safety of TTFields plus weekly paclitaxel in 31 PROC (platinum-resistant ovarian cancer) patients...

Full Text